Industry Trends

Latest stories

14 Shares

5 Lessons Learned from the Pandemic for Commercial Life Sciences with Insights from Novartis

17 Shares

A Year of Digital-First Engagement

6 Shares

By The Numbers

Trending Now

649 Views0 Comments
in Headlines

Alladapt Announces Completion of Oversubscribed $119 Million Institutional Financing

Menlo Park, CA., June 22, 2022 (GLOBE NEWSWIRE) — Alladapt Immunotherapeutics Inc., a private, clinical-stage biopharmaceutical company developing prescription therapeutics to address IgE-mediated food allergy, announced today the closing of a $119 million financing round led by Enavate Sciences, a portfolio company created by Patient Square Capital. Additional investors participating in the financing include Alladapt’s founding investor, Gurnet Point Capital, along with new investors Allerfund, Novartis (NYSE: NVS), Red Tree Venture Capital, and WestRiver Group. More

by hsandm June 22, 2022, 4:56 pm

Read More
393 Views0 Comments
in Headlines

Angiex Strengthens its Leadership Team with the Appointment of Marty J. Duvall as Chief Executive Officer

Cambridge, MA, June 22, 2022 (PRNewswire) — Angiex, developer of Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapies for solid cancers, has appointed Marty J. Duvall as chief executive officer and member of its board of directors. More

by hsandm June 22, 2022, 4:24 pm

Read More
745 Views0 Comments
in Headlines

Inimmune’s new CEO Alan Joslyn takes the helm

Missoula, MT., June 21, 2022 (PRNewswire) — Inimmune Corp., a leader in developing the next generation of vaccines and immunotherapeutics, announced today that Dr. Alan Joslyn has been appointed President and Chief Executive Officer of the company. Dr. Joslyn will also join the Inimmune Board of Directors as CEO. More

by hsandm June 21, 2022, 4:50 pm

Read More
2 Shares492 Views0 Comments
in Headlines

Precision BioSciences and Novartis ink 1.5B In Vivo Gene Editing Collaboration

Durham, N.C. June 21, 2022 (BUSINESS WIRE) — Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced it has entered into an exclusive worldwide in vivo gene editing research and development collaboration and license agreement with Novartis Pharma AG (the “Agreement”). As part of the Agreement, Precision will develop a custom ARCUS nuclease that will be designed to insert, in vivo, a therapeutic transgene at a “safe harbor” location in the genome as a potential one-time transformative treatment option for diseases including certain hemoglobinopathies such as sickle cell disease and beta thalassemia. More

by hsandm June 21, 2022, 4:17 pm

Read More
8 Shares869 Views0 Comments
in Headlines

Israel’s Aidoc raises $110m for AI tech that reads imaging scans

New York, NY, June 20, 2022 (The Times of Israel) — Aidoc, a maker of AI-based software that helps radiologists read medical scans and alerts them to strokes or pulmonary embolisms, has pulled in a $110 million Series D investment round to expand the development of its technology, sales and its market reach, the company said last week. More

by hsandm June 20, 2022, 4:47 pm

Read More
11 Shares993 ViewsComments Off on Mineralys Therapeutics Closes $118 Million Oversubscribed Series B Financing to Advance the Development of Novel, Targeted Treatment for Hypertension
in Headlines

Mineralys Therapeutics Closes $118 Million Oversubscribed Series B Financing to Advance the Development of Novel, Targeted Treatment for Hypertension

Philadelphia, PA., June 8, 2022 (PRNewswire) — Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company committed to developing a best-in-class, novel therapy for the treatment of hypertension, today announced the completion of an oversubscribed and up-sized $118 million Series B financing. More

by hsandm June 8, 2022, 7:47 pm

Read More

Industry Trends

Latest stories

5 Lessons Learned from the Pandemic for Commercial Life Sciences with Insights from Novartis

A Year of Digital-First Engagement

By The Numbers

More stories

BioPharma’s COVID-19 Response, Market Forecast & M&A

Industry Trends: By the numbers

Beyond COVID-19: Life sciences reimagined

By the numbers

Pharma, Biotech and MedTech Half-Year Review from Evaluate Vantage

Industry Trends: By the numbers

The Orphan Drug Outlook

Metrics on Covid-19: Highlights of the Evaluate Vantage Report

INDUSTRY TRENDS: BY THE NUMBERS

Life Science Industry Outlook: 2019 In Review and 2020 Trends to Watch

INDUSTRY TRENDS: BY THE NUMBERS

VANTAGE 2020 PREVIEW

Alladapt Announces Completion of Oversubscribed $119 Million Institutional Financing

Angiex Strengthens its Leadership Team with the Appointment of Marty J. Duvall as Chief Executive Officer

Inimmune’s new CEO Alan Joslyn takes the helm

Precision BioSciences and Novartis ink 1.5B In Vivo Gene Editing Collaboration

Israel’s Aidoc raises $110m for AI tech that reads imaging scans

Mineralys Therapeutics Closes $118 Million Oversubscribed Series B Financing to Advance the Development of Novel, Targeted Treatment for Hypertension

Latest stories

More stories

Log In

Sign In

Forgot password?

Your password reset link appears to be invalid or expired.

Log in

Privacy Policy

Add to Collection

No Collections